# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy rat...
JMP Securities analyst Jonathan Wolleben initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform...
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goa...
Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $55 price target.
For the year ending December 31, 2024, Rhythm anticipates approximately $250 million to $270 million in Non-GAAP Operating Expe...
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate o...